Vicus Therapeutics, Morristown, NJ, is a biopharmaceutical company dedicated to bringing breakthrough adjunct therapies to patients with cancer. Vicus' lead investigational therapy, VT-122, is a combination of etodolac and propranolol. VT-122 showed positive results in a Phase 2 clinical trial of lung cancer patients and is in a Phase 2 clinical trial in advanced cancer patients receiving active therapy.